We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ATE market cap is 15.52M. The company's latest EPS is CAD -0.3701 and P/E is -0.78.
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 9.54M | 9.99M | 10.95M | 13.6M | 6.99M |
| Operating Income | -12.19M | -16.24M | -24.47M | -22.02M | -14.96M |
| Net Income | -12.82M | -19.34M | -26.3M | -25.06M | -19.48M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 14.82M | 13.84M | 81.74M | 89.16M | 70.56M |
| Total Liabilities | 7.38M | 10.06M | 31.48M | 32.33M | 30.4M |
| Total Equity | 7.44M | 3.78M | 50.26M | 56.83M | 40.17M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -7.06M | -11.94M | -105k | -16.92M | -16.31M |
| Investing | -257k | 98k | -264k | -20.22M | -11.83M |
| Financing | 9.59M | 12M | 66.16M | -26k | 80k |
| Market Cap | 15.52M |
| Price to Earnings Ratio | -0.78 |
| Price to Sales Ratio | 2.18 |
| Price to Cash Ratio | 2.26 |
| Price to Book Ratio | 0.38 |
| Dividend Yield | - |
| Shares Outstanding | 52.62M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 477.09k |
| 52 Week Change | -46.36% |
| 52 Week High | 1.23 |
| 52 Week Low | 0.15 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Antibe Therapeutics Inc |
| Address |
15 prince arthur avenue toronto, ontario M5R 1B2 |
| Website | https://www.antibethera.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
